Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Retained Earnings (2021 - 2025)

Zymeworks' Retained Earnings history spans 5 years, with the latest figure at -$6.1 million for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 12.56% to -$6.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.1 million, a 12.56% increase, with the full-year FY2025 number at -$6.1 million, up 12.56% from a year prior.
  • Retained Earnings hit -$6.1 million in Q4 2025 for Zymeworks, roughly flat from -$6.0 million in the prior quarter.
  • Over the last five years, Retained Earnings for ZYME hit a ceiling of -$5.9 million in Q1 2023 and a floor of -$850.7 million in Q2 2025.
  • Historically, Retained Earnings has averaged -$148.5 million across 5 years, with a median of -$6.7 million in 2021.
  • Biggest five-year swings in Retained Earnings: skyrocketed 99.1% in 2024 and later crashed 10662.32% in 2025.
  • Tracing ZYME's Retained Earnings over 5 years: stood at -$6.7 million in 2021, then changed by 0.0% to -$6.7 million in 2022, then increased by 0.84% to -$6.6 million in 2023, then decreased by 5.29% to -$7.0 million in 2024, then grew by 12.56% to -$6.1 million in 2025.
  • Business Quant data shows Retained Earnings for ZYME at -$6.1 million in Q4 2025, -$6.0 million in Q3 2025, and -$850.7 million in Q2 2025.